There has been a significant amount of noise surrounding the recent announcement that the federal government is moving medical cannabis to Schedule 3 under the Drug Enforcement Administration’s controlled substances framework. While many headlines made it sound like a sweeping legalization moment, the reality is more nuanced. It is a meaningful step forward, but understanding its true impact requires considering both the opportunities and the limitations of this policy shift.

Here is a breakdown of what the Schedule 3 move actually means for the cannabis industry, and specifically, what it means for us here in Vermont.

What Actually Changed?

The most critical detail that often gets lost in the coverage is that this rescheduling applies strictly to medical cannabis, not recreational cannabis.

This means that while it impacts state-legal medical programs, it does not apply to adult-use (recreational) markets, nor does it federally legalize cannabis. It represents partial progress rather than a full transformation of cannabis law.

The Core Benefit: 280E Tax Relief

Moving cannabis from Schedule 1 to Schedule 3 signals a major shift in how the federal government views the plant’s medical value. However, the most substantial immediate impact for businesses is tax relief.

Under Section 280E of the tax code, cannabis businesses have historically been unable to deduct ordinary business expenses, severely compressing margins across the industry. With the move to Schedule 3, medical cannabis operators may now become eligible for standard business deductions. This potential improvement in profitability creates crucial room for businesses to reinvest in their patients, their staff, and product quality.

Nationally, the benefits will be uneven. The operators who benefit most will be those in states with large, active medical programs or those heavily focused on medical patients.

What This Means for Vermont

We have to be honest about our local reality: Vermont is currently a recreational-first market. Our medical program is small, and most consumers shop within the adult-use system due to barriers in medical access, such as costs and qualification limits.

For medical operators in the state, such as Vermont Patients Alliance and Zenbarn Farms, this change does matter in a targeted way. The shift offers potential tax relief on the medical side of the business, granting more flexibility to price products affordably for patients and reinvest in better medical offerings. However, because the medical side is still a small slice of the overall market, this federal change is not an immediate game-changer for most Vermont operators.

The Bigger Opportunity: Rebuilding Vermont’s Medical Program

If Vermont leaders are paying attention, this federal shift should serve as a catalyst for state-level action. For this change to have a real impact, the state needs to revitalize its medical program

Meaningful steps would include:

  • Expanding qualifying conditions: Allowing more people to legally access medical cannabis.
  • Reducing barriers to entry: Lowering costs and simplifying the process of obtaining a medical card.
  • Increasing patient awareness: Educating the public, as many people do not realize they may qualify.
  • Aligning pricing advantages: Ensuring that medical cannabis is meaningfully more affordable than recreational options.

If these steps are taken, the Schedule 3 shift could help grow Vermont’s medical program, leading to lower prices over time, more consistent products, and better overall access for patients.

The Bottom Line

The Schedule 3 shift is a step forward, but it is not the finish line. It offers recognition of medical value and potential tax relief, but it is limited by its lack of application to the recreational market.
We still need full federal legalization. That is the only way to eliminate 280E across the board, normalize banking and financing, and create a fair, stable national market.

At Zenbarn Farms and Vermont Patients Alliance, we view this shift as a valuable tool to better serve our medical patients and a clear signal that momentum is building. It is also a reminder that the work is not done. If we want a cannabis system that truly serves patients, consumers, and communities equitably, we must keep pushing forward.